We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+5%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$40.3B
AUM Growth
+$535M
(+1.3%)
Cap. Flow
-$468M
Cap. Flow
% of AUM
-1.16%
Top 10 Holdings %
Top 10 Hldgs %
15.78%
Holding
2,279
New
170
Increased
711
Reduced
1,071
Closed
189
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$178M |
| 2 |
LyondellBasell Industries
LYB
|
+$133M |
| 3 |
AT&T
T
|
+$124M |
| 4 |
Stanley Black & Decker
SWK
|
+$101M |
| 5 |
Pfizer
PFE
|
+$93.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$229M |
| 2 |
Gilead Sciences
GILD
|
+$164M |
| 3 |
Broadcom
AVGO
|
+$149M |
| 4 |
KeyCorp
KEY
|
+$145M |
| 5 |
Darden Restaurants
DRI
|
+$125M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.22% |
| 2 | Technology | 14.47% |
| 3 | Financials | 10.84% |
| 4 | Industrials | 9.01% |
| 5 | Consumer Discretionary | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Rogers Corp
ROG
$2.36B
| $64.8M | 0.16% |
399,979
+54,513
| +16% | +$8.65M |
|
152
Equifax
EFX
$20.2B
| $64.7M | 0.16% |
274,859
+28,153
| +11% | +$5.93M |
|
153
Chubb
CB
$132B
| $64.6M | 0.16% |
335,370
-3,042
| -0.9% | -$596K |
|
154
Rhythm Pharmaceuticals
RYTM
$7.05B
| $64.2M | 0.16% |
3,891,683
| – | – |
|
155
Repligen
RGEN
$9.48B
| $63.7M | 0.16% |
450,477
-184
| -0% | -$29.5K |
|
156
RPM International
RPM
$12.9B
| $63.3M | 0.16% |
705,671
+48,418
| +7% | +$3.98M |
|
157
PTC
PTC
$14.8B
| $62.9M | 0.16% |
441,972
+82,253
| +23% | +$10.9M |
|
|
GMS
158
DELISTED
GMS Inc
GMS
| $62.7M | 0.16% |
905,698
+105,938
| +13% | +$6.55M |
|
159
Lam Research
LRCX
$342B
| $62.5M | 0.16% |
972,130
-5,310
| -0.5% | -$299K |
|
160
Cheniere Energy
LNG
$56.6B
| $62.3M | 0.15% |
409,066
-515
| -0.1% | -$76.2K |
|
161
Royal Caribbean
RCL
$68.3B
| $62.2M | 0.15% |
599,427
+154,201
| +35% | +$12.1M |
|
162
General Mills
GIS
$19.5B
| $62M | 0.15% |
808,365
-15,185
| -2% | -$1.3M |
|
163
XPO
XPO
$21.1B
| $61.9M | 0.15% |
1,049,563
-231,029
| -18% | -$10.5M |
|
164
Adobe
ADBE
$106B
| $61.7M | 0.15% |
126,153
+6,873
| +6% | +$2.77M |
|
|
HES
165
DELISTED
Hess
HES
| $61.5M | 0.15% |
452,448
+3,465
| +0.8% | +$474K |
|
166
Corcept Therapeutics
CORT
$12.1B
| $61.4M | 0.15% |
2,760,296
| – | – |
|
167
Nike
NKE
$55B
| $61M | 0.15% |
552,749
-81,182
| -13% | -$9.49M |
|
|
168
KeyCorp
KEY
$23.4B
| $60.4M | 0.15% |
6,538,873
-13,870,798
| -68% | -$145M |
|
169
Ares Management
ARES
$29.9B
| $60.2M | 0.15% |
625,000
| – | – |
|
|
SPLK
170
DELISTED
Splunk Inc
SPLK
| $60.2M | 0.15% |
567,120
+35,578
| +7% | +$3.38M |
|
171
Atkore
ATKR
$3.18B
| $60.1M | 0.15% |
385,199
-22,257
| -5% | -$2.92M |
|
172
Prudential Financial
PRU
$41.2B
| $60M | 0.15% |
679,584
+29,446
| +5% | +$2.46M |
|
173
Novanta
NOVT
$5.3B
| $59.8M | 0.15% |
324,744
-71,923
| -18% | -$11.8M |
|
174
Zoom
ZM
$27.8B
| $59.7M | 0.15% |
878,903
+109,012
| +14% | +$7.29M |
|
175
MoonLake Immunotherapeutics
MLTX
$1.08B
| $59.6M | 0.15% |
1,169,499
+365,000
| +45% | +$9.82M |
|
Similar funds
Federated Hermes's Q2 2023 Portfolio in Review
As of Q2 2023, Federated Hermes held 2,279 positions worth $40.3B, up 1.3% from $39.7B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Federated Hermes's Q2 2023 filing shows 170 new, 711 increased, 1,071 reduced and 189 closed positions. Its largest new stake was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M. The largest sale was Clorox, an estimated $229M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 20% a quarter earlier, followed by Technology and Financials.
- Federated Hermes's largest Q2 2023 buy was HashiCorp, Inc. Class A Common Stock: 1,317,400 shares worth $34.5M.
- Federated Hermes added most to Amgen in Q2 2023, an estimated $178M increase.
- Federated Hermes's biggest Q2 2023 reduction was Clorox, cutting an estimated $229M.
- Federated Hermes fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $55.4M.
- Federated Hermes's ten largest holdings make up 16% of its $40.3B portfolio in Q2 2023.
- Federated Hermes opened 170 new positions and closed 189 in Q2 2023.
- Federated Hermes's portfolio value rose 1.3% quarter-over-quarter to $40.3B.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.